CUREVAC NV (1CVAC.MI) Stock Price, Forecast & Analysis
Europe • Euronext Milan • BIT:1CVAC • NL0015436031
1CVAC.MI Key Statistics, Chart & Performance
The current stock price of 1CVAC.MI is 4.386 EUR.
1CVAC.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1CVAC.MI.
1CVAC.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1CVAC.MI. 1CVAC.MI is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
1CVAC.MI Financial Highlights
Over the last trailing twelve months 1CVAC.MI reported a non-GAAP Earnings per Share(EPS) of 0.58. The EPS increased by 20.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 182.11% | ||
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.03 |
1CVAC.MI Forecast & Estimates
12 analysts have analysed 1CVAC.MI and the average price target is 4.03 EUR. This implies a price decrease of -8.09% is expected in the next year compared to the current price of 4.386.
For the next year, analysts expect an EPS growth of -170.56% and a revenue growth -86.75% for 1CVAC.MI
1CVAC.MI Ownership
1CVAC.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.83 | 43.442B | ||
| ARGX | ARGENX SE | 28.11 | 43.417B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.254B | ||
| ABVX | ABIVAX SA | N/A | 7.695B | ||
| 2X1 | ABIVAX SA | N/A | 7.656B | ||
| GXE | GALAPAGOS NV | N/A | 1.856B | ||
| GLPG | GALAPAGOS NV | N/A | 1.854B | ||
| IVA | INVENTIVA SA | N/A | 992.256M | ||
| 6IV | INVENTIVA SA | N/A | 978.821M | ||
| NANO | NANOBIOTIX | N/A | 936.79M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1CVAC.MI
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG DE
Employees: 904
Phone: 49707198830
CUREVAC NV / 1CVAC.MI FAQ
What does CUREVAC NV do?
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Can you provide the latest stock price for CUREVAC NV?
The current stock price of 1CVAC.MI is 4.386 EUR. The price decreased by -4.82% in the last trading session.
What is the dividend status of CUREVAC NV?
1CVAC.MI does not pay a dividend.
How is the ChartMill rating for CUREVAC NV?
1CVAC.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is CUREVAC NV worth?
CUREVAC NV (1CVAC.MI) has a market capitalization of 987.60M EUR. This makes 1CVAC.MI a Small Cap stock.
Can you provide the upcoming earnings date for CUREVAC NV?
CUREVAC NV (1CVAC.MI) will report earnings on 2026-04-08, after the market close.